<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817074</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG051641</org_study_id>
    <secondary_id>1R01AG052583-01</secondary_id>
    <nct_id>NCT02817074</nct_id>
  </id_info>
  <brief_title>MIND Diet Intervention and Cognitive Decline</brief_title>
  <acronym>MIND</acronym>
  <official_title>MIND Diet Intervention to Prevent Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III randomized controlled trial designed to test the effects of a 3-year intervention&#xD;
      of the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) on cognitive&#xD;
      decline and brain neurodegeneration among 600 individuals 65+ years without cognitive&#xD;
      impairment who are overweight and have suboptimal diets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) is a Phase III&#xD;
      randomized controlled trial designed to test the effects of a 3-year intervention of a hybrid&#xD;
      of the Mediterranean and DASH diets, called MIND, on cognitive decline among 600 individuals&#xD;
      65+ years without cognitive impairment who are overweight and have suboptimal diets. The&#xD;
      proposed MIND diet is a hybrid of the Mediterranean and DASH diets but with selected&#xD;
      modifications based on the most compelling evidence in the diet-dementia field. The MIND diet&#xD;
      has the same basic components of the DASH and Mediterranean diets, such as emphasis on&#xD;
      natural plant-based foods and limited animal and high saturated fat foods, but uniquely&#xD;
      specifies green leafy vegetables and berries as well as food component servings that reflect&#xD;
      the nutrition-dementia evidence. The trial will employ a parallel group design comparing the&#xD;
      effects on cognitive outcomes of the MIND intervention diet plus mild caloric restriction for&#xD;
      weight loss to the control diet, usual diet with mild caloric restriction for weight loss.&#xD;
      Biological effects of the MIND diet will be assessed by measurement of brain macro- and&#xD;
      micro-structural integrity in 300 randomly selected participants. Other biochemical markers&#xD;
      will be assessed in the entire cohort of 600 participants, including: plasma Abeta 42/Abeta&#xD;
      40, brain-derived neurotrophic factor (BDNF) and plasma markers of oxidative stress and&#xD;
      inflammation. In addition, the trial will examine potential effect mediators and modifiers by&#xD;
      a number of cardiovascular risk factors, AD biomarkers, and biological mechanisms. The&#xD;
      proposed study has two clinical sites, one in Chicago (Rush University) and one in Boston&#xD;
      (Harvard University), and centralized laboratories for data coordinating and analyses&#xD;
      (Brigham &amp; Women's Hospital), neuroimaging analyses (Rush University), and specialized&#xD;
      laboratories for tissue biochemical analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in global cognitive function (composite score)</measure>
    <time_frame>3 years</time_frame>
    <description>Global cognitive function assessment is based on a battery of 12 cognitive tests [1. Word list Memory; 2. Word List Recall; 3. Word List Recognition; 4. Logical Memory (East Boston Story Immediate Recall); 5. Logical Memory (East Boston Story Delayed Recall); 6. Verbal Fluency; 7. Multilingual Naming Test; 8. Trail A; 9. Trail B; 10. Flanker Inhibitory Control; 11. Oral Symbol Digit Modalities Test; and 12. Pattern Comparison. Individual test scores will be summarized by calculating the z-score for each test based on the mean and standard deviation of the sample distribution - averaging z-scores across tests will yield a composite score for global cognitive function. Cognitive function will be assessed at the baseline, 6, 12, 24, and 36 months to determine the time-course of cognitive change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in specific cognitive domains</measure>
    <time_frame>3 years</time_frame>
    <description>Change in specific cognitive domains: episodic memory, semantic memory, perceptual speed, and executive function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in brain MRI total brain /intracranial volume (cubic centimeters) and hippocampal/intracranial volume (cubic centimeters)</measure>
    <time_frame>3 years</time_frame>
    <description>Changes in brain MRI-derived normalized measures of total brain volume (cubic centimeters) and hippocampal volume (cubic centimeters) and white/gray matter, segmented gray matter regions, white matter lesions, and thickness of segmented cortical regions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory aim 1: Incidence of cardiovascular disease</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the risk of incident cardiovascular disease. Cardiovascular disease is defined as the presence of coronary heart disease, cerebrovascular disease, and/or heart failure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 2a: Blood pressure</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of systolic and diastolic blood pressure (mmHg) from the baseline to 6, 12, 24, and 36 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 2b: Total cholesterol</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of total cholesterol (mg/dL), in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 2c: Low-density lipoprotein (LDL)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of LDL (mg/dL) in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 2d: High-density lipoprotein (HDL)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of HDL (mg/dL) in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 2e: Hemoglobin A1c (HbA1c)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of HbA1c levels in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 3: Plasma amyloid beta (Abeta)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of plasma Abeta 40 (pg/ml), Abeta42 (pg/ml), and ratio Abeta40/Abeta42 from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4a: C-Reactive Protein (CRP)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of CRP (mg/L) levels in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4b: Interleukin 6 (IL-6)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of plasma IL-6 (pg/mL) from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4c: Oxidized LDL</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of oxidized LDL (mg/dl) in plasma from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4d: Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of eGFR (mg/dL) from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4e: Brain-derived neurotrophic factor</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of plasma Brain-derived neurotrophic factor (pg/mL) from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory aim 4f: Adiponectin</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the role of MIND diet on the change of plasma adiponectin (mg/L) levels from the baseline to 3 and 36 months.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">604</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Dementia</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>MIND Diet +Weight loss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Diet + Weight Loss</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MIND Diet</intervention_name>
    <description>3-year dietary counseling to adhere to the MIND diet and for mild weight loss</description>
    <arm_group_label>MIND Diet +Weight loss</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mild Weight Loss</intervention_name>
    <description>3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss</description>
    <arm_group_label>MIND Diet +Weight loss</arm_group_label>
    <arm_group_label>Usual Diet + Weight Loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  family history of dementia&#xD;
&#xD;
          -  BMI &gt;=25&#xD;
&#xD;
          -  suboptimal diet&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  heavy alcohol use&#xD;
&#xD;
          -  severe illness&#xD;
&#xD;
          -  cognitively impaired&#xD;
&#xD;
          -  psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa L Barnes, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard School of Public Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morris MC, Tangney CC, Wang Y, Sacks FM, Barnes LL, Bennett DA, Aggarwal NT. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015 Sep;11(9):1015-22. doi: 10.1016/j.jalz.2015.04.011. Epub 2015 Jun 15.</citation>
    <PMID>26086182</PMID>
  </reference>
  <reference>
    <citation>Morris MC, Tangney CC, Wang Y, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14. doi: 10.1016/j.jalz.2014.11.009. Epub 2015 Feb 11.</citation>
    <PMID>25681666</PMID>
  </reference>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>March 21, 2022</last_update_submitted>
  <last_update_submitted_qc>March 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Lisa L. Barnes, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Electronic data will be made available after trial completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

